華潤雙鶴(600062.SH):搭建“人工智能驅動的創新藥物開發與概念驗證平臺”,利用AI技術對藥物發現提供支持
格隆匯3月12日丨華潤雙鶴(600062.SH)在互動平臺表示,公司新藥研發的核心在前段主要是化合物篩選,通過靶點的設計利用AI智能進行化合物篩選,能夠快速找到先導化合物。公司搭建“人工智能驅動的創新藥物開發與概念驗證平臺”,利用AI技術對藥物發現提供支持,現此平臺已成功入選北京市概念驗證平臺和朝陽區數字醫療概念驗證平臺,爲生物醫藥企業及科研院所提供創新藥物研發全鏈條專業服務,助力生物醫藥科技成果高效轉化與落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.